^
    Back
    Association details:
    Biomarker:EGFR L858R
    Cancer:Non Small Cell Lung Cancer
    Drug:Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) +
    gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

    Excerpt:
    Exposure (24 hours) of H1975 to combined PKI-587 and HKI-272 (250 nmol/L) markedly increased suppression of p-Akt (T308; IC50 < 30 nmol/L), increased caspase 3/7 activity (Supplementary Fig. 5C), and induced cPARP at 30 nmol/L or more...When PKI-587 (5 mg/kg, d×5 once) was given in combination with HKI-272 (40 mg/kg, po daily) significantly (P < 0.02), more antitumor effect than either compound given alone was observed in a 14-day study...
    DOI:
    10.1158/1078-0432.CCR-10-1694